Spruce Biosciences, Inc. (SPRB)

Market Cap	16.52M
Revenue (ttm)	7.10M
Net Income (ttm)	-39.43M
Shares Out	41.30M
EPS (ttm)	-0.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	320,738
Open	0.382
Previous Close	0.382
Day's Range	0.374 - 0.400
52-Week Range	0.370 - 5.950
Beta	2.34
Analysts	Hold
Price Target	2.17 (+442.5%)
Earnings Date	Nov 11, 2024

About SPRB

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric clas...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 9, 2020
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRB
• Website: https://www.sprucebiosciences.com

Analyst Forecast

According to 7 analysts, the average rating for SPRB stock is "Hold." The 12-month stock price forecast is $2.17, which is an increase of 442.50% from the latest price.

Price Target

$2.17

(442.50% upside)

Analyst Consensus: Hold